Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Preferred Stock Liabilities (2021 - 2024)

Senti Biosciences has reported Preferred Stock Liabilities over the past 3 years, most recently at $25.1 million for Q4 2024.

  • For Q4 2024, Preferred Stock Liabilities changed N/A year-over-year to $25.1 million; the TTM value through Dec 2024 reached $25.1 million, changed N/A, while the annual FY2024 figure was $25.1 million, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q4 2024 was $25.1 million at Senti Biosciences, down from $171.8 million in the prior quarter.
  • Over five years, Preferred Stock Liabilities peaked at $171.8 million in Q2 2021 and troughed at $25.1 million in Q4 2024.
  • A 3-year average of $134.1 million and a median of $171.8 million in 2021 define the central range for Preferred Stock Liabilities.
  • On a YoY basis, Preferred Stock Liabilities climbed as much as 86.86% in 2022 and fell as far as 86.86% in 2022.
  • Year by year, Preferred Stock Liabilities stood at $171.8 million in 2021, then changed by 0.0% to $171.8 million in 2022, then crashed by 85.39% to $25.1 million in 2024.
  • Business Quant data shows Preferred Stock Liabilities for SNTI at $25.1 million in Q4 2024, $171.8 million in Q1 2022, and $171.8 million in Q4 2021.